ADCT — ADC Telecommunications
Unknown Industry · Unknown Sector
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. The company is engaged in developing antibody drug conjugates for the treatment of patients with hematological malignancies and solid tumors. The company's FDA-approved and marketed product ZYNLONTA (loncastuximab tesirine) is a CD19-targeted antibody-alkylator conjugate for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline includes LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, which are being developed for the treatment of various cancer indications. Geographically, the company's largest revenue source is the United States, followed by Europe, the Middle East, and Africa (EMEA).
Key Facts
| Status | Active |
| Sector | Unknown Sector |
| Industry | Unknown Industry |
| Joined | 1999-07-30 |
| Tenure | 7 yrs |
S&P 500 Timeline
1999-07-30Joined S&P 500
2007-07-02Removed from S&P 500
Industry Peers
—
Sector Peers
—
Data source:
Wikipedia · CC BY-SA 4.0 · Updated 2026-07-10